SB202190, a widely used inhibitor of p38 MAPKα and β, was recently described to induce autophagic vacuoles and cell death in colon and ovarian cancer cells lines and, therefore, this effect was supposed to be specific for transformed cells and to open therapeutic options. Here, we demonstrate that SB202190 and the structurally related inhibitor SB203580 induce pro-autophagic gene expression and vacuole formation in various cancer and non-cancer cell lines of human, rat, mouse and hamster origin. This effect seems to induce defective autophagy leading to the accumulation of acidic vacuoles, p62 protein and lipid conjugated LC3. Using further p38 inhibitors we show that p38 MAPK inhibition is not sufficient for the autophagic response. In line with these results, expression of a SB202190-resistant mutant of p38α, which significantly increases activity of the p38 pathway under inhibitory conditions, does not block SB202190-dependent vacuole formation, indicating that lack of p38α activity is not necessary for this effect. Obviously, the induction of autophagic vacuole formation by SB203580 and SB202190 is due to off-target effects of these inhibitors on post-translational protein modifications, such as phosphorylation of the MAPKs ERK1/2 and JNK1/2, ribosomal protein S6, and PKB/Akt. Interestingly, the PI3K-inhibitor wortmannin induces transient vacuole formation indicating that the PI3K-PKB/Akt-mTOR pathway is essential for preventing autophagy and that cross-inhibition of this pathway by SB202190 could be the reason for the early part of the effect observed.
SB202190, a widely used inhibitor of p38 MAPKα and β, was recently described to induce autophagic vacuoles and cell death in colon and ovarian cancer cells lines and, therefore, this effect was supposed to be specific for transformed cells and to open therapeutic options. Here, we demonstrate that SB202190 and the structurally related inhibitor SB203580 induce pro-autophagic gene expression and vacuole formation in various cancer and non-cancer cell lines of human, rat, mouse and hamster origin. This effect seems to induce defective autophagy leading to the accumulation of acidic vacuoles, p62 protein and lipid conjugated LC3. Using further p38 inhibitors we show that p38 MAPK inhibition is not sufficient for the autophagic response. In line with these results, expression of a SB202190-resistant mutant of p38α, which significantly increases activity of the p38 pathway under inhibitory conditions, does not block SB202190-dependent vacuole formation, indicating that lack of p38α activity is not necessary for this effect. Obviously, the induction of autophagic vacuole formation by SB203580 and SB202190 is due to off-target effects of these inhibitors on post-translational protein modifications, such as phosphorylation of the MAPKs ERK1/2 and JNK1/2, ribosomal protein S6, and PKB/Akt. Interestingly, the PI3K-inhibitor wortmannin induces transient vacuole formation indicating that the PI3K-PKB/Akt-mTOR pathway is essential for preventing autophagy and that cross-inhibition of this pathway by SB202190 could be the reason for the early part of the effect observed.
Small molecule protein kinase inhibitors are largely being developed for the treatment of a variety of human diseases [1], [2]. p38 MAPK has been identified as a potential target of such small molecules for the treatment of cancer and inflammation [3]. SB203580 and SB202190 are the most widely used inhibitors of the p38 MAPK pathway. The gate keeper threonine (T) 106 in the ATP-binding groove of p38α was shown to be the major determinant for the specificity of this class of compounds. The majority of the known protein kinases carry a bulky residue at T106 equivalent position, which prevents binding of SB203580 and SB202190 [4], [5]. Although the SB compounds were thought to specifically inhibit the α and β isoforms of p38 MAPK leading to suppression of inflammatory gene expression, later studies identified several further protein kinase targets of these compounds including GAK, GSK3β, RICK (RIP2), Casein kinase I, Type-II TGF receptor, LCK, CRAF (Raf-1), BRAF and PDK1 [5], [6], [7]. In addition, at higher concentrations SB compounds were shown to have inhibitory effects on several non-protein kinase targets, such as hepatic cytochrome P450 enzymes [8], cyclooxygenases and thromboxane synthase [9].SB202190 was shown to induce autophagic vacuoles and cell death in a colon-cancer specific manner [10]. This observation was recently extended to ovarian cancer cells [11] and suggested an important role of p38 MAPK and serious therapeutic potential for SB202190 in colon cancer treatment. The observed macro-autophagy is an evolutionarily conserved process highly active during differentiation and development, consisting of the sequestration of cytoplasmic proteins and organelles into autophagosome, with subsequent degradation in the autophagolysosomes [12], [13]. While the major regulator of autophagy is the mTOR pathway, which regulates the rate of autophagy in response to nutrient availability [14], recent studies have demonstrated the importance of p38 and ERK1/2 MAPK signaling in the formation and maturation of autophagic vacuoles in response to starvation and several other chemical stresses [15], [16], [17], [18]. Furthermore, inhibition of p38 MAPK by SB202190 was demonstrated to induce transcriptional reprogramming which involves a shift from HIF-1α-dependent to Foxo-3A-dependent pro-autophagic gene expression leading to type-II programmed cell death [19]. The vacuoles induced by SB compounds were unusually large and, hence, reminiscent of blockade of autophagic clearance rather than an efficient autophagic flux. Here, we analyzed the effect of SB202190 with the aim to further characterize the nature of this cell-type specific vacuolation response and the role of p38 MAPK in autophagy. Unexpectedly, our results indicate that neither inhibition of p38 MAPK nor the gene expression changes are necessary for the SB202190-mediated autophagic response, which seems to be cell type- but not cancer-specific. Instead, SB202190 interferes with various signaling pathway including PI3K/Akt/mTOR signaling, which could be responsible for the autophagic response observed.
Results
SB202190 induces cytoplasmic vacuoles in a cell type-specific manner in transformed and non-transformed cells
SB202190 is the most widely used p38 MAPK inhibitor. Treatment with 5 µM SB202190 reproducibly induced vacuole formation in various cell lines while it does not in other cells (Figure 1, Table 1). The induction of vacuole formation does not correlate with the transformation status of the cells, since it is detected also in non-transformed cell lines (BHK21, IEC6, RGM1) as well as primary cells (HUVEC, MEFs, hMSC) and could not be detected in some of the transformed cells tested (HeLa, Sh-SY5Y, WM1617, WM793). Vacuoles were clearly visible in most of the sensitive cell lines after approximately 2 h of SB202190 treatment.
Figure 1
Cell type-specific induction of vacuoles by SB202190.
Indicated cells were treated with 5 µM SB202190 or solvent control (DMSO) for 12 h and phase contrast images taken using a 20× objective a and 30× digital camera magnification factor.
Table 1
Cell type-specific vacuole formation induced by SB202190.
No
Cell line
Species
Cell type
Vacuoles
1
AGS
Human
gastric adenocarcinoma
+
2
A549
Human
lung carcinoma
+
3
BHK21
Hamster
adult kidney fibroblast
+
4
C2C12
Mouse
Myoblast
−
5
Caco-2-Bbe
Human
colorectal adenocarcinoma
+
6
HEK293T
Human
embryonic kidney
−
7
HeLa
Human
cervical adenocarcinoma
−
8
hMSC
Human
mesenchymal stem cells
+
9
HT29
Human
colorectal adenocarcinoma
+
10
HUVEC
Human
endothelial cells
+
11
IEC6
Rat
small intestinal epithelium
+
12
L929
Mouse
Fibrosarcoma
+
13
MEF
Mouse
embryonic fibroblast
+
14
NIH 3T3
Mouse
embryonic fibroblast
−
15
RGM1
Rat
gastric epithelium
+
16
Sh-SY5Y
Human
Neuroblastoma
−
17
WM1617
Human
Melanoma
−
18
WM793
Human
Melanoma
−
Cell type-specific induction of vacuoles by SB202190.
Indicated cells were treated with 5 µM SB202190 or solvent control (DMSO) for 12 h and phase contrast images taken using a 20× objective a and 30× digital camera magnification factor.
SB202190 induces accumulation of enlarged autophagolysosomes in HT29 cells
Previous studies have reported colon cancer-specific induction of vacuoles and autophagic cell death by SB202190. Since this effect was originally analyzed and characterized for its autophagic key features in detail in HT29 humancolon cancer cells [10], we continued to analyze the SB202190 effect in this cell line, too. Autophagy is characterized by the sequestration of cytoplasmic contents by membranous autophagosomes and degradation by the lysosomal pathway. The autophagosomes are usually ultrastructures often visualized by electron microscopy and hence the very large vacuoles induced by SB202190 probably represent artifacts of an immature autophagic response. As shown by acridine orange (AO) and neutral red staining of SB202190-treated HT29 cells, the vacuoles were highly acidic (Figure 2A, left panel). SB202190-induced vacuoles were also positive for the presence of the lysosomal membrane protein LAMP2 (Figure 2A, middle panel). Induction of autophagy is characterized by the conversion of microtubule-associated protein 1 light chain 3 (LC3) to a lipid conjugated form, LC3-II, and its recruitment to autophagic vacuoles forming a distinct punctuate staining pattern [20]. After SB202190 treatment, transfected YFP-tagged LC3 showed punctate structures close to the enlarged vacuoles, but did not co-localize with the vacuoles (Figure 2A, right panel). This is similar to the abnormal autophagolysosomes observed in sertoli cells upon lindane treatment [15]. Since these vacuoles are LAMP2 positive, acidic and hence of lysosomal origin, we quantified the SB202190-induced vacuolation response by assessing the acidic vacuolar content by acridine orange (AO) staining. For that reason, we stained SB202190-treated HT29 cells and measured the red fluorescence of AO by FACS. A significant time-dependent up regulation of red fluorescence of AO in response to SB202190 treatment could clearly be detected (Figure 2B).
Figure 2
Characterization of SB202190-induced vacuoles in HT29 cells.
(A) HT29 human colorectal adenocarcinoma cells were treated with 5 µM SB202190 or solvent control (DMSO) for 24 hours and living cells were stained with neutral red or acridine orange (AO) (left panel). Neutral red accumulated in the acidic vacuoles within 10 minutes. AO stained the nucleus and cytoplasm green with the acidic vacuoles visible as orange-yellow structures. Cells treated with DMSO or 5 µM SB202190 for 6 hours were stained for LAMP2 after para-formaldehyde fixation (middle panel). HT29 cells were transiently transfected with YFP-LC3 construct, 24 hours post transfection treated with 5 µM SB202190 for additional 24 hours or left untreated and analyzed for YFP fluorescence (right panel). LC3 dots are detected close to the large non-stained vacuoles. (B) HT29 cells were treated with 5 µM SB202190 for indicated times, stained with AO and red fluorescence (FL3 channel) was quantified by FACS. The change of mean fluorescence was calculated and shown in the right panel. (C) Cells in complete growth medium were treated with 5 µM SB202190 or 50 nM rapamycin in the presence or absence of 200 µg/mL leupeptin for indicated time points. Ratios of the band intensities for LC3-II to LC3-I is plotted in the right panel (D) HT29 cells were treated with SB202190 (5 µM) in the presence or absence of 10 mM 3-methyl adenine for 12 h. (E) Percentage of vacuolated cells were calculated from 3 independent images and plotted in the right panel.
Characterization of SB202190-induced vacuoles in HT29 cells.
(A) HT29 humancolorectal adenocarcinoma cells were treated with 5 µM SB202190 or solvent control (DMSO) for 24 hours and living cells were stained with neutral red or acridine orange (AO) (left panel). Neutral red accumulated in the acidic vacuoles within 10 minutes. AO stained the nucleus and cytoplasm green with the acidic vacuoles visible as orange-yellow structures. Cells treated with DMSO or 5 µM SB202190 for 6 hours were stained for LAMP2 after para-formaldehyde fixation (middle panel). HT29 cells were transiently transfected with YFP-LC3 construct, 24 hours post transfection treated with 5 µM SB202190 for additional 24 hours or left untreated and analyzed for YFP fluorescence (right panel). LC3 dots are detected close to the large non-stained vacuoles. (B) HT29 cells were treated with 5 µM SB202190 for indicated times, stained with AO and red fluorescence (FL3 channel) was quantified by FACS. The change of mean fluorescence was calculated and shown in the right panel. (C) Cells in complete growth medium were treated with 5 µM SB202190 or 50 nM rapamycin in the presence or absence of 200 µg/mL leupeptin for indicated time points. Ratios of the band intensities for LC3-II to LC3-I is plotted in the right panel (D) HT29 cells were treated with SB202190 (5 µM) in the presence or absence of 10 mM 3-methyl adenine for 12 h. (E) Percentage of vacuolated cells were calculated from 3 independent images and plotted in the right panel.We also analyzed endogenous LC3 in HT29 cells by western blotting. There is a significant level of basal LC3-II in HT29 cells, which is not further increased by 2 h of SB202190 treatment. However, SB202190 treatment together with lysosomal protease inhibitor led to further accumulation of lipid conjugated LC3, suggesting the presence of active autophagic flux (Figure 2C). Other markers for autophagic response, such as Beclin-1 and ATG12-ATG5, showed no significant changes (data not shown). Interestingly, the treatment of HT29 cells with rapamycin, an inhibitor of mTOR and a commonly used autophagy inducer, also showed similar autophagic turnover, as monitored by the LC3-II/LC3-I ratio in the presence and absence of protease inhibitor (Figure 2C). It was interesting to note that rapamycin did not induce the formation of vacuoles (data not shown). Consistent with previous studies, treatment with 3 methyl adenine (3MA), a class III PI3 kinase inhibitor and inhibitor of autophagy could suppress SB202190-induced vacuole formation (Figure 2D, E). Additionally, chloroquine, an inhibitor of lysosomal acidification, and wortmannin, a broad spectrum PI3 kinase inhibitor, also prevented vacuole formation (Figure S1). Thus, PI3 kinase activity, LC3lipid conjugation and lysosomal acidification seem prerequisites for the vacuolation response.
SB202190 treatment leads to non-productive autophagy and accumulation of autophagic substrates
Involvement of p38 MAPK in autophagy regulation is complex and different studies have suggested opposing roles for the pathway in starvation induced autophagy. Hence, we hypothesized that the differences between rapamycin and SB202190 could be due to a late effect of p38 inhibition which blocks autophagolysosome resolution, and hence accumulation of these acidic vacuoles. To prove this hypothesis we monitored the levels of p62, a substrate protein preferably degraded by the autophagic pathway in SB202190 and rapamycin treated cells in parallel [21]. Rapamycin did not drastically affect endogenous p62 protein levels in HT29 cells, while SB202190 strongly up regulated p62 levels in HT29 cells at later time points (Figure 3A, B). Lipid conjugated LC3 (LC3 II) also accumulated at 12 and 24 h of SB202190 treatment, supporting a model of enhanced lipid conjugation and reduced flux by lysosomal degradation (Figure 3A). We further verified this by analyzing the autophagic turnover of LC3-II and p62 in the presence or absence of leupeptin, a lysosomal protease inhibitor. When HT29 cells were treated with SB202190, a time-dependent accumulation of p62 and LC3-II independent of the presence or absence of leupeptin was observed (Figure 3C, E & F). In contrast, rapamycin treatment alone did not show significant effects on the levels of LC3-II or p62. Rapamycin in combination with leupeptin led to strong LC3lipid conjugation and a small, but significant up regulation of p62 (Figure 3D, E & F). This observation conclusively demonstrates that in the identical cellular system, the turnover of autophagy substrates are differentially affected by rapamycin and SB202190. Rapamycin induces active autophagic proteolysis sensitive to leupeptin treatment, while SB202190 induces non-productive autophagy, accumulation of p62 and LC3-II. In addition nutrient starvation-induced autophagic proteolysis was also significantly suppressed by SB202190 treatment (Figure S2).
Figure 3
Differential effects of SB202190 and rapamycin on autophagic proteolysis.
(A) Cells were treated for indicated time periods with 50 nM rapamycin or 5 µM SB202190 and lysates were analyzed for LC3b and p62 levels by western blotting. (B) p62 band intensities from panel A was quantified using Image J software, normalized to gapdh and plotted. (C) HT29 cells were treated for indicated time periods with SB202190 (10 µM) in the presence or absence of 200 µg/mL leupeptin and autophagy substrates analyzed by western blot (D) Cells were treated with rapamycin (100 nM) alone or in combination with leupeptin and analyzed (E) LC3-II band intensities from panel C and D were quantified as in panel B (F) p62 band intensities from panel C and D were quantified as described in panel B.
Differential effects of SB202190 and rapamycin on autophagic proteolysis.
(A) Cells were treated for indicated time periods with 50 nM rapamycin or 5 µM SB202190 and lysates were analyzed for LC3b and p62 levels by western blotting. (B) p62 band intensities from panel A was quantified using Image J software, normalized to gapdh and plotted. (C) HT29 cells were treated for indicated time periods with SB202190 (10 µM) in the presence or absence of 200 µg/mL leupeptin and autophagy substrates analyzed by western blot (D) Cells were treated with rapamycin (100 nM) alone or in combination with leupeptin and analyzed (E) LC3-II band intensities from panel C and D were quantified as in panel B (F) p62 band intensities from panel C and D were quantified as described in panel B.
SB202190-induced de-novo gene expression is not necessary for vacuolation in HT29 cells
SB202190-induced autophagic response and vacuole accumulation was previously reported to involve a transcriptional reprogramming leading to up regulation of pro-autophagic genes [19], a role which is not established at the moment [21]. Therefore, we decided to characterize the influence of changes in gene expression in SB202190-induced vacuole formation. 24 hours of SB202190 treatment led to a small, but consistent increase in the expression of GABARAP, a homolog of LC3 (Atg8), and of BNIP3L, a protein involved in autophagy and apoptosis (Figure 4A). This transcriptional up regulation of GABARAP and related genes were reported to be due to Foxo3A activation [19], [22]. To monitor transcriptional activity of Foxo, we generated stable Fork head response element reporter (FHRE-luc)-integrated HT29 cells. Interestingly, SB202190 induced FHRE-luc reporter activity was observed only after 48 h of SB202190 treatment (Figure 4B). This raised the question whether SB202190-induced transcriptional response is the direct reason for or a downstream effect of the vacuolation response. To determine whether SB202190-induced vacuole formation is dependent on the up regulation of autophagy related transcripts, we treated the cells with the transcriptional inhibitor actinomycin-D (Act-D). Treatment with Act-D had no effect on the kinetics of SB202190-induced vacuole formation in HT29 cells, challenging the role of de novo gene expression in the vacuolation response (Figure 4C, D). Analysis of GABARAP, LC3 and BNIP3L expression by RT-PCR showed very small induction after 2 h of SB202190 treatment which was effectively suppressed by Act-D (Figure 4E). Thus, our results demonstrate that SB202190-induced transcriptional reprogramming cannot be the reason for the primary effect of vacuole formation but could be a downstream effect of accumulated vacuoles. Insignificant up regulation of the GABARAP related transcripts at 2 h time point and very late induction of the FHRE-luc reporter supports this model.
Figure 4
SB202190-induced transcriptional changes are not necessary for vacuole formation in HT29 cells.
(A) HT29 cells were treated in the presence of DMSO or SB202190 (5 µM) for 24 hours and the levels of BNIP3L and GABARAP mRNAs were analyzed by RT- PCR. The relative mRNA levels were normalized to actin mRNA and plotted (* denotes p-value<0.04). (B) HT29 cells stably transfected with FHRE-luc reporter were treated with 10 µM SB202190 for indicated time points and luciferase activity measured and normalized to protein content. (C) Cells seeded in 12 well plates were treated with Act-D (5 µg/mL), SB202190 (5 µM) or both together and phase contrast images were taken at indicated time points (original magnification 600×). (D) Percentage of vacuolated cells was calculated using Image J software. Percentage vacuolated-cells plotted is the average of three measurements from three independent images. (E) HT29 cells treated as indicated were analyzed by RT- PCR for the expression of GABARAP, BNIP3L and LC3.
SB202190-induced transcriptional changes are not necessary for vacuole formation in HT29 cells.
(A) HT29 cells were treated in the presence of DMSO or SB202190 (5 µM) for 24 hours and the levels of BNIP3L and GABARAP mRNAs were analyzed by RT- PCR. The relative mRNA levels were normalized to actin mRNA and plotted (* denotes p-value<0.04). (B) HT29 cells stably transfected with FHRE-luc reporter were treated with 10 µM SB202190 for indicated time points and luciferase activity measured and normalized to protein content. (C) Cells seeded in 12 well plates were treated with Act-D (5 µg/mL), SB202190 (5 µM) or both together and phase contrast images were taken at indicated time points (original magnification 600×). (D) Percentage of vacuolated cells was calculated using Image J software. Percentage vacuolated-cells plotted is the average of three measurements from three independent images. (E) HT29 cells treated as indicated were analyzed by RT- PCR for the expression of GABARAP, BNIP3L and LC3.
p38 MAPK inhibition is not sufficient for SB202190-induced vacuole formation and LC3-II accumulation
We then analyzed the vacuolation response in HT29 cells using further p38 MAPK inhibitors (SB203580, BIRB-796 and VX-745) as well as SB202474, an inactive analogue of the SB compounds, as negative control. While SB202190 and SB203580 induce vacuoles, the two other potent inhibitors of p38 MAPK, BIRB-796 and VX-745, unexpectedly failed to induce vacuoles in HT29 cells (Figure 5A, B). Vacuole formation in SB202190- and SB203580-treated cells correlated with the late stage up regulation of LC3-II, which is not up-regulated in response to BIRB-796 and VX-745 (Figure 5C). We monitored FHRE-luc reporter activity between SB202190 and BIRB-796 treated HT29 cells and detected enhanced reporter activity only in response to SB202190 treatment (Figure 5D). Regardless of the ability to induce vacuoles, all inhibitors tested efficiently blocked p38 MAPK α and β activity in these cells as shown by the reduction of phosphorylation of the p38 MAPK substrate MK2 at threonine T334 and its downstream targets Hsp27 (serine S82) and keratin 20 (serine S13) (Figure 5E). We also analyzed the effect of siRNA mediated depletion of p38α on vacuole formation. Even though the siRNA transfection procedure marginally increased the percentage of vacuolated cells, the effect of p38α down regulation was not statistically significant (Figure S3),
Figure 5
p38 MAPK inhibition is neither sufficient for induction of autophagy nor for FHRE reporter activation.
(A) HT29 cells were treated for 24 hours with SB203580 (5 µM), SB202190 (5 µM), SB202474 (5 µM), BIRB-796 (1 µM), VX- 745 (2 µM) and DMSO control. Cells were fixed in 95% ethanol and stained with crystal violet (original magnification 600×). (B) The percentage of vacuolated cells from three independent images was calculated and the mean values are shown. (C) Cells treated with the set of inhibitors as indicated were analyzed by Western blotting for the autophagic marker – LC3b. LC3-I and its lipid conjugated form- LC3-II are indicated. Gapdh was used as loading control. (D) HT29 cells stably transfected with FHRE-luc reporter were treated with 10 µM SB202190 or 1 µM BIRB-796 for indicated time points and luciferase activity measured and normalized to protein content. (E) Cells were treated with the respective inhibitors or DMSO for 1 hour as indicated, followed by 30 minutes treatment with anisomycin (10 µg/ml) or DMSO. For confirming p38 inhibition, the phosphorylations of MK2, keratin 20 and Hsp27 were monitored by Western blotting. Total Hsp27 and gapdh were used as loading controls.
p38 MAPK inhibition is neither sufficient for induction of autophagy nor for FHRE reporter activation.
(A) HT29 cells were treated for 24 hours with SB203580 (5 µM), SB202190 (5 µM), SB202474 (5 µM), BIRB-796 (1 µM), VX- 745 (2 µM) and DMSO control. Cells were fixed in 95% ethanol and stained with crystal violet (original magnification 600×). (B) The percentage of vacuolated cells from three independent images was calculated and the mean values are shown. (C) Cells treated with the set of inhibitors as indicated were analyzed by Western blotting for the autophagic marker – LC3b. LC3-I and its lipid conjugated form- LC3-II are indicated. Gapdh was used as loading control. (D) HT29 cells stably transfected with FHRE-luc reporter were treated with 10 µM SB202190 or 1 µM BIRB-796 for indicated time points and luciferase activity measured and normalized to protein content. (E) Cells were treated with the respective inhibitors or DMSO for 1 hour as indicated, followed by 30 minutes treatment with anisomycin (10 µg/ml) or DMSO. For confirming p38 inhibition, the phosphorylations of MK2, keratin 20 and Hsp27 were monitored by Western blotting. Total Hsp27 and gapdh were used as loading controls.
SB202190-induced acidic vacuolation response in HT29 cells proceeds in the presence of p38 MAPK activity
The above experiments demonstrated that inhibition of p38 MAPK alone is not sufficient to explain the massive vacuole accumulation observed in HT29 cells. However, several studies from different genetic models have shown a role for p38 MAPK in the regulation of autophagy [17], [18], [23] and a recent study has proposed that p38 MAPK α inhibits autophagy by interfering with the intracellular trafficking of Atg9 [18]. p38 and ERK MAP kinases were shown to coordinately regulate autophagosome maturation [15], [24]. Additionally, MK2, a bonafide substrate of p38 MAPK, was identified as a negative regulator of basal autophagic response in a recent siRNA screen [25]. Since p38 MAPK signaling is therefore important for the regulation of autophagy, we then asked the question whether lack of p38 MAPK activity is necessary for SB-induced autophagolysosome formation, at least. We addressed this question by using the SB-resistant mutant p38 MAPKα-T106M, which fails to bind to and which is not inhibited by SB203580 or SB202190, but otherwise displays normal activation, inhibition by BIRB-796 and activity towards substrates [26], [27]. HT29 cells stably transduced with p38 MAPKα-T106M displayed significantly enhanced anisomycin-induced activity in the presence of SB202190 when compared to cells transduced with wild type p38 MAPK or control vector, as monitored by activation of the MK2-bonafide substrate keratin 20 at serine S13 (Figure 6B) [28]. In contrast to this difference in p38 MAPK activity, there were no significant differences observed between these cells in SB202190-induced vacuole formation (Figure 6A, C). Similar results were obtained for SB203580-induced vacuolization (data not shown). The increase in acidic vacuolar content quantified by AO staining and FACS scan did not show any significant difference between these cell lines, even though there were minor differences in the kinetics of vacuole acidification (Figure 6D). This conclusively shows that down regulation of p38 MAPK activity is not critical for SB-induced accumulation of defective autolysosomes.
Figure 6
Inhibition of p38 MAPKα is not necessary for SB202190-induced acidic vacuole formation.
(A) HT29 cells stably transduced with empty vector or vectors expressing wild type p38α or mutant p38α T106M were treated as indicated. Phase contrast images were taken at indicated time points (original magnification 600×) (B) p38α-, p38α T106M- or empty vector-transduced cells were treated with 5 µM SB202190 or DMSO as indicated and anisomycin-induced p38 activity monitored by the phosphorylation of keratin 20, a bonafide substrate of MK2. p38 and Hsc70 expression are shown as controls. (C) Percentage of vacuolated cells after 6 hours of SB202190 treatment were calculated and plotted. (D) Stably transduced cells were treated for indicated times with 5 µM SB202190, stained with AO and analyzed by FACS as described in Figure 2F.
Inhibition of p38 MAPKα is not necessary for SB202190-induced acidic vacuole formation.
(A) HT29 cells stably transduced with empty vector or vectors expressing wild type p38α or mutant p38α T106M were treated as indicated. Phase contrast images were taken at indicated time points (original magnification 600×) (B) p38α-, p38α T106M- or empty vector-transduced cells were treated with 5 µM SB202190 or DMSO as indicated and anisomycin-induced p38 activity monitored by the phosphorylation of keratin 20, a bonafide substrate of MK2. p38 and Hsc70 expression are shown as controls. (C) Percentage of vacuolated cells after 6 hours of SB202190 treatment were calculated and plotted. (D) Stably transduced cells were treated for indicated times with 5 µM SB202190, stained with AO and analyzed by FACS as described in Figure 2F.
SB202190-specific signalling events in HT29 cells
Since the primary effect of SB202190 on vacuolization is independent of de novo gene expression, we hypothesized that modification of post-translational signaling reflected by changes in phosphorylation events could be responsible. To further characterize these mechanisms, we analyzed the effects of SB202190 on phosphorylations involved in key intracellular signaling cascades, such as the regulatory phosphorylations of ERK-, JNK-, and PKB/Akt as well as S6-phosphorylation, and compared these effects with those of BIRB-796 in HT29 cells. While BIRB-796 did not affect the basal phosphorylation of these components, SB202190 strongly suppressed the phosphorylation of ERK1/2-T202/Y204 and S6 ribosomal protein-S235/236, significantly inhibited the PKB/Akt-T308 phosphorylation and up-regulated Phospho-JNK1/2-T183/Y185 (Figure 7A).
Figure 7
Modulation of different signaling pathways by SB202190 in HT29 cells and analysis of their role in vacuolation response.
(A) HT29 cells were treated with BIRB-796 (1 µM) or SB202190 (5 µM) for indicated times and analyzed by Western blotting with the indicated antibodies. Hsc70 and gapdh were used as loading controls. (B) Cells were treated for 12 h with the indicated inhibitors or solvent control, fixed in 95% ethanol and stained with crystal violet (original magnification 600×). (C) Cells were treated with SB202190 or wortmannin and live cell images (original magnification 600×) were acquired at indicated time points. (D) HT29, WM1617 and WM793 maintained in complete growth medium were treated with indicated concentrations of SB202190, PD098059 or BIRB-796 for 90 minutes. Lysates were analyzed for phosphorylation of ERK1/2. Hsc70 was used as loading control.
Modulation of different signaling pathways by SB202190 in HT29 cells and analysis of their role in vacuolation response.
(A) HT29 cells were treated with BIRB-796 (1 µM) or SB202190 (5 µM) for indicated times and analyzed by Western blotting with the indicated antibodies. Hsc70 and gapdh were used as loading controls. (B) Cells were treated for 12 h with the indicated inhibitors or solvent control, fixed in 95% ethanol and stained with crystal violet (original magnification 600×). (C) Cells were treated with SB202190 or wortmannin and live cell images (original magnification 600×) were acquired at indicated time points. (D) HT29, WM1617 and WM793 maintained in complete growth medium were treated with indicated concentrations of SB202190, PD098059 or BIRB-796 for 90 minutes. Lysates were analyzed for phosphorylation of ERK1/2. Hsc70 was used as loading control.We then asked the question, whether small molecules, which suppress phosphorylation of ERK1/2 and PKB/Akt similar to SB202190 in HT29 cells, such as PD098059, a specific inhibitor of the ERK upstream kinases MEK1/2, and wortmannin, a specific inhibitor of PI3K, are able to induce vacuolization in these cells. Furthermore, we analyzed whether SB202190-induced JNK activation in HT29 cells is required for SB202190-induced vacuolization. Inhibition of ERK1/2 signaling in HT29 cells by PD098059 did not induce vacuoles (Figure 7B). Similarly, JNK1/2 inhibition had no effect on SB202190- induced vacuole formation (Figure 7B), indicating that modulation of ERK1/2 and JNK1/2 activity by SB202190 is not responsible for vacuolization in HT29 cells. Interestingly, treatment of HT29 cells with the PI3K inhibitor wortmannin induced transient vacuolization in HT29 cells, which peaks after about 2 h but disappears almost completely after 4 h (Figure 7C). This indicates that the PI3Kpathway is involved in early vacuole formation in HT29 cells, and that a cross-inhibition of this pathway by SB202190, as suggested by the reduced PKB/Akt phosphorylation, could be the mechanism for SB202190-induced vacuolization. Since the PDK1 inhibitor BX912 is not able to induce vacuolization in HT29 cells (data not shown), the interference of SB202190 with the PI3K-pathway is probably more upstream. When controlling the efficiency of inhibition of ERK1/2 phosphorylation by PD098059, a very effective and specific inhibitor of MEK1/2, for the above experiments, we were excited to see that SB202190 is able to inhibit ERK1/2 phosphorylation in HT29 cells similarly and even in lower concentrations (Figure 7D). Since SB202190 was so far not described as an efficient MEK1/2 inhibitor, we tested various other cell lines for SB202190-mediated inhibition of ERK1/2 phosphorylation (Table 2). Interestingly, only two other humanmelanoma cell lines, WM793 and WM1617, display an influence of SB202190 on phospho-ERK1/2 (Figure 7D). Since it is known that HT29, WM793 and WM1617 carry the oncogenic BRAF-V600E mutation (30) and the other cells tested do not have this mutation, the cell type-specific effect of SB202190 on ERK1/2 phosphorylation could be BRAF-V600E-dependent. However, regardless to the interesting ability of SB202190 to target the ERK pathway in these cells, this property does not correlate with vacuolization (cf. Table 2).
Table 2
Vacuole formation does not correlate with pERK1/2 down regulation.
No
Cell line
Vacuoles
pERK1/2 ↓
1
AGS
+
−
2
BHK21
+
−
3
Caco-2-Bbe
+
−
4
HEK293T
−
−
5
HeLa
−
−
6
HT29
+
+
7
L929
+
−
8
Sh-SY5Y
−
−
9
WM1617
−
+
10
WM793
−
+
pERK1/2 ↓ denotes SB202190 induced down regulation of ERK1/2 phosphorylation.
pERK1/2 ↓ denotes SB202190 induced down regulation of ERK1/2 phosphorylation.
Discussion
Several studies have shown an evolutionarily conserved role for p38 MAPK in the regulation of autophagy [17], [18], [29]. However, the cell type-specific induction of defective autophagic vacuoles by SB202190 and SB203580 seen in colon cancerHT29 cells, which we extended to other transformed and non-transformed cells types including primary cells, is a p38 MAPK-independent effect of these compounds. This effect of SB compounds in HT29 cells seems to be biphasic, involving an initial phase which leads to initiation of LC3 conjugation and active autophagic degradation followed by the blockade of autophagic proteolysis, leading to the accumulation of acidic vacuoles, p62 and LC3-II. Using further inhibitors of p38 MAPK and a SB-resistant mutant of p38 MAPKα, we could show that inhibition of p38 MAPK is not sufficient for this effect and that the effect even does not require suppression of p38 MAPK activity. Since vacuolization is also detected after Act-D treatment, the cell type-specific changes in pro-autophagic gene expression reported in colon cancer [19], [30] and other cells [17] in response to SB202190 treatment seem to be dispensable for the formation of acidic autolysosomes. The kinetics of vacuole formation, gene expression and FHRE reporter activation suggest that changes in gene expression could be a feed-forward control of already induced vacuoles, or a result of blockade of basal autophagy, leading to accumulation of enlarged autophagolysosomes and cell death. Contradictory data exist in the literature about the correlation between p38 activity, Foxo3A transcriptional activation and pro-autophagic gene expression [19], [31]. Since these studies utilized SB compounds to study the involvement of p38, these effects needs to be re-evaluated.A wide panel of SB202190 targets has been identified in vitro and in vivo
[6], [7], [32], [33], [34], [35]. Many of these targets including BRAF [36], RIP3 [37], GAK [38], PDK1 [39] and GSKβ [40] have been associated with lysosomal functions, autophagy and caspase-independent cell death. A unique off-target responsible for the SB202190-induced autophagic response seems unlikely, since treatment with a panel of specific and broad spectrum small molecule inhibitors including those targeting previously identified off-targets did not yield the autophagic phenotype in HT29 cells (data not shown). siRNA mediated down-regulation of GAK, GSK3β, RIP2 and RIP3 also did not induce formation of vacuoles (data not shown). It is rather likely that multiple off-target effects culminate in the autophagolysosome formation in a cell type-specific manner. Interestingly, wortmannin induced a transient formation of vacuoles in HT29 cells. The induction of acidic vacuoles by wortmannin has also been reported previously in a normal rat kidney cell line [41]. PI3 kinase family members are shown to positively and negatively regulate autophagy. SB202190-induced autophagic response seems to be biphasic and it could be possible that the initial phase requires PI3 kinase inhibition. Since the PDK1 inhibitor BX912 does not induce vacuolization, only a direct effect of SB202190 on PI3K in a cell type-specific manner could explain the early effects observed. A very recent study by Szyniarowski et al have demonstrated the formation of defective autophagosomes upon specific knock down of WNK2 [25]. It is interesting to note that WNK2 amino acid sequence analysis in the p38α-T106 homologous region suggest that this kinase could be SB202190-sensitive (Figure S4). However, as discussed above, multiple off-target effects of SB202190 could probably culminate in non-productive autophagy and accumulation of defective autolysosomes and further detailed studies are required to characterize the mechanism.Swollen macro-autophagosomes, similar to SB202190-induced vacuoles, were reported recently in primary smooth muscle cells in response to sodium channel blockers [42]. ATP-dependent ion channels and nutrient transporters could be potential non-kinase targets of the SB compounds: SB203580 and SB202190 were shown to affect cellular nucleoside uptake, but this effect was also caused by the inactive variant SB202474 [41] which did not induce vacuoles in HT29 cells. SB202190-induced vacuole formation as well as LC3 conjugation in HT29 cells was enhanced in glucose-pyruvate free medium, but suppressed upon amino acid starvation (M.B.M, unpublished). Targeting cancer cell-specific metabolism for treatment is a sought-after option [43] and the role played by glucose and amino acids for autophagy in HT29 cells and colon cancer should be evaluated in more detail.Here, we also describe an inhibitory effect of SB202190 on ERK1/2 activation. SB203580 was previously shown to inhibit BRAF and CRAF in vitro (31). With the supporting data that SB203580 and SB202190 bind to BRAF and displayed greater affinity for BRAF-V600E in-vitro (32), we propose that BRAF-V600E could sensitize the ERK pathway to SB202190. We demonstrate that SB202190 behaves like a BRAF-V600E-specific inhibitor similar to SB-590885 [44] and PLX4720 [45]. BRAF-V600E-mutated cell lines are solely dependent on RAF/MEK/ERK signaling for survival and this oncogene addiction makes RAF/MEK inhibitors relevant compounds for treatment of cancer [46]. Recent studies could show a positive regulatory role for BRAF-V600E in melanoma cell autophagy [36] and enhanced LC3lipid conjugation in the presence of hyper activated BRAF. However, we demonstrate that the cell line-specific existence of the BRAF-mutation and the ability of SB202190 to inhibit the ERK1/2 pathway do not correlate with the cell line-specific vacuolization induced by SB202190 indicating that other pathways, such as PI3K/PKB/Akt, are responsible for the effects observed.
Materials and Methods
Materials
SB203580 (Calbiochem, 559389), SB202474 (Calbiochem, 559387), PD098059 (Calbiochem, 513000), BIRB-796 (Axon Medchem, 1358) and SB202190 (Axon Medchem, 1364) stocks were prepared in DMSO. Phospho specific antibodies against ERK1/2 (#9106), S6 protein (#4858), MK2-T334 (#3041), JNK1/2 (#9255), Akt-T308 (#4056) and total antibodies for LC3b (#2775), Beclin-1 (#3738), p38 (#9212) and ATG12 (#2010) were from Cell signaling Technology. ERK2 (sc-1647) and Hsp27 (sc-1048) antibodies were from Santa Cruz Biotechnology, Other antibodies used were pHsp27-S82 (Invitrogen, 44536), Hsc70 (Stressgen, SPA815), LAMP2 (DSHB-University of Iowa, H4B4-s), pS13-keratin-20 (Gift from Omary, MB) and gapdh (Chemicon international, MAB374). siGENOME SMART pool siRNA for hMAPK14 (p38α) and negative control siRNA were from Dharmacon. Anisomycin, actinomycin-D, acridine orange, neutral red, crystal violet and G418 were purchased from Sigma-Aldrich.
Cell culture and treatment
HT29 [10], Caco-2 Bbe [47], AGS [48], WM1617 and WM793 [49] cells were maintained in DMEM/F12 medium with 10% FCS and with 20% FCS for Sh-SY5Y [50] (neuroblastoma cells). All other cell lines were grown in DMEM with 10% FCS. Cells were seeded in 12 well plates for experiments and treated as mentioned in the figure legends. For nutrient starvation, cells were washed with PBS and cultured in EBSS (Earle's balanced salt solution). After treatments the cells were washed with PBS and lysed directly in SDS gel loading buffer. LC3-YFP plasmid was transfected into HT29 cells using lipofectamine LTX reagent using manufacturer's protocol. siRNA transfections were performed using Hiperfect reagent (Qiagen) using standard protocol.
Cell staining and Microscopy
Cells were imaged using a Leica DM IL LED microscope and Leica EC3 camera. Phase contrast or fluorescent images of live cells were taken or cells were fixed with 95% ethanol and stained with 0.5% crystal violet and observed. For AO staining, stock solution (5 mg/mL in water) was added to culture medium to a final concentration of 5 µg/mL, incubated for 15 minutes, medium changed and observed under the microscope with GFP filter settings. For neutral red staining a 1000× stock in DMSO (28 mg/mL) was used, cells were treated similarly and bright field images were acquired. Immunofluorescence staining of HT29 cells was performed as described previously [28].
FACS-scan for acidic vacuole quantification
Acidic vacuoles were quantified by FACS using a modification of a reported method [51]. Cells after indicated treatments were trypsinized and re-suspended in PBS with 0.5 µg/mL AO and incubated at room temperature for 20 minutes. The suspension was diluted 1∶1 with PBS and the FL3 channel fluorescence analyzed using an Accuri –C6 flow cytometer.
Immuno blotting
Cell lysates were separated on 7.5–16% gradient denaturing poly acrylamide gels and transferred to Hybond ECL membranes, blocked in 5% BSA-PBS-0.1% Tween-20 for an hour, followed by primary antibodies in the block buffer over night at 4°C. Horse-radish peroxidase-conjugated secondary antibodies (Santa Cruz, sc-2005, 2004, 2033 and 2032) were used and the blots were developed with a self-made ECL detection kit, and the digital chemiluminescence images were taken by a Luminescent Image Analyzer LAS-3000 (Fujifilm).
Real Time PCR
Cells were treated in 12 well plates and processed as described earlier using SYBR Green chemistry [52]. Actin mRNA was used for normalization. The primer sequences for GABARAP, MAP1LC3A (LC3), BNIP3L and GLUT1 (SLC2A1) are available on request.
Generation of stable reporter cell line and luciferase assays
Fork Head Response element reporter plasmid was a gift from Dr. Alex Toker and has been reported earlier [53]. The reporter plasmid was co transfected with pEGFP-C1 vector (Clontech) into HT29 cells using Polyethylenimine reagent [54]. 24 hour post transfection cells were treated with 750 µg/mL G418 (geniticin) for additional 10 days. Clones were isolated by serial dilution and cells were analyzed for luciferase activity and GFP fluorescence. For reporter assays, cells were treated in 12 well plates and luciferase activity determined as reported earlier [52]. The firefly luciferase values were normalized to protein content.
Generation of HT29 cells stably transduced with p38 T106M
Retroviral vector expressing wild-type humanp38α is reporter earlier [52]. Thr106 residue was mutated to methionine using Quik Change site directed mutagenesis kit (Stratagene). Virus particles were obtained by transfecting the constructs into 293-GPG cells. HT29 cells were treated with viral supernatants and transduced cells selected in the presence of 600 µg/mL Hygromycin-B.Wortmannin (Wm) and Chloroquine (CQ) inhibit SB202190 induced vacuole formation. HT29 cells in complete growth medium were treated with 5 µM SB202190 alone or in combination with with 1 µM Wm for 24 hours (A), 70 µM CQ for 6 hours (B).(TIF)Click here for additional data file.Nutrient starvation induced autophagic proteolysis is partially inhibited by SB202190. (A) HT29 cells were left in complete growth medium or were nutrient starved in EBSS (Earle's balanced salt solution) alone or in combination with SB202190 or Leupeptin for indicated time points and samples were analyzed by western blotting with the indicated antibodies. The band intensities for LC3-II (B) and p62 (C) were quantified by image J software, normalized to gapdh and plotted.(TIF)Click here for additional data file.p38α knock down does not induce significant vacuolation in HT29 cells. HT29 cells were transfected with the indicated siRNAs or were left untreated. Images were acquired 48 h post transfection (A) and the percentage of vacuolated cells, calculated from three independent images were plotted with standard deviation (B). Cells were lysed and analyzed by western blotting for p38α expression. The percentage expression is plotted after normalization to loading control.(TIF)Click here for additional data file.WNK2 (“with no lysine kinase 2”) is a potential SB target. Alignment of humanp38α (iso-2) and WNK2 (human) kinase domains. Red box indicates the conserved lysine (K) residue in subdomain II which is replaced by cysteine (C) in WNK2. The blue box indicates the gate keeper residue, T106 in p38α which is M/Q/L (bulky residues) in most kinases, which determines the sensitivity to the SB compounds.(TIF)Click here for additional data file.
Authors: Klaus Godl; Josef Wissing; Alexander Kurtenbach; Peter Habenberger; Stephanie Blencke; Heidrun Gutbrod; Kostadinos Salassidis; Matthias Stein-Gerlach; Andrea Missio; Matt Cotten; Henrik Daub Journal: Proc Natl Acad Sci U S A Date: 2003-12-10 Impact factor: 11.205
Authors: R J Gum; M M McLaughlin; S Kumar; Z Wang; M J Bower; J C Lee; J L Adams; G P Livi; E J Goldsmith; P R Young Journal: J Biol Chem Date: 1998-06-19 Impact factor: 5.157
Authors: Abbas Raza; Jessica W Crothers; Mahalia M McGill; Gary M Mawe; Cory Teuscher; Dimitry N Krementsov Journal: J Leukoc Biol Date: 2017-09-06 Impact factor: 4.962
Authors: Daniel J Klionsky; Kotb Abdelmohsen; Akihisa Abe; Md Joynal Abedin; Hagai Abeliovich; Abraham Acevedo Arozena; Hiroaki Adachi; Christopher M Adams; Peter D Adams; Khosrow Adeli; Peter J Adhihetty; Sharon G Adler; Galila Agam; Rajesh Agarwal; Manish K Aghi; Maria Agnello; Patrizia Agostinis; Patricia V Aguilar; Julio Aguirre-Ghiso; Edoardo M Airoldi; Slimane Ait-Si-Ali; Takahiko Akematsu; Emmanuel T Akporiaye; Mohamed Al-Rubeai; Guillermo M Albaiceta; Chris Albanese; Diego Albani; Matthew L Albert; Jesus Aldudo; Hana Algül; Mehrdad Alirezaei; Iraide Alloza; Alexandru Almasan; Maylin Almonte-Beceril; Emad S Alnemri; Covadonga Alonso; Nihal Altan-Bonnet; Dario C Altieri; Silvia Alvarez; Lydia Alvarez-Erviti; Sandro Alves; Giuseppina Amadoro; Atsuo Amano; Consuelo Amantini; Santiago Ambrosio; Ivano Amelio; Amal O Amer; Mohamed Amessou; Angelika Amon; Zhenyi An; Frank A Anania; Stig U Andersen; Usha P Andley; Catherine K Andreadi; Nathalie Andrieu-Abadie; Alberto Anel; David K Ann; Shailendra Anoopkumar-Dukie; Manuela Antonioli; Hiroshi Aoki; Nadezda Apostolova; Saveria Aquila; Katia Aquilano; Koichi Araki; Eli Arama; Agustin Aranda; Jun Araya; Alexandre Arcaro; Esperanza Arias; Hirokazu Arimoto; Aileen R Ariosa; Jane L Armstrong; Thierry Arnould; Ivica Arsov; Katsuhiko Asanuma; Valerie Askanas; Eric Asselin; Ryuichiro Atarashi; Sally S Atherton; Julie D Atkin; Laura D Attardi; Patrick Auberger; Georg Auburger; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Maria Laura Avantaggiati; Limor Avrahami; Suresh Awale; Neelam Azad; Tiziana Bachetti; Jonathan M Backer; Dong-Hun Bae; Jae-Sung Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Seung-Hoon Baek; Stephen Baghdiguian; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xue-Yuan Bai; Yannick Bailly; Kithiganahalli Narayanaswamy Balaji; Walter Balduini; Andrea Ballabio; Rena Balzan; Rajkumar Banerjee; Gábor Bánhegyi; Haijun Bao; Benoit Barbeau; Maria D Barrachina; Esther Barreiro; Bonnie Bartel; Alberto Bartolomé; Diane C Bassham; Maria Teresa Bassi; Robert C Bast; Alakananda Basu; Maria Teresa Batista; Henri Batoko; Maurizio Battino; Kyle Bauckman; Bradley L Baumgarner; K Ulrich Bayer; Rupert Beale; Jean-François Beaulieu; George R Beck; Christoph Becker; J David Beckham; Pierre-André Bédard; Patrick J Bednarski; Thomas J Begley; Christian Behl; Christian Behrends; Georg Mn Behrens; Kevin E Behrns; Eloy Bejarano; Amine Belaid; Francesca Belleudi; Giovanni Bénard; Guy Berchem; Daniele Bergamaschi; Matteo Bergami; Ben Berkhout; Laura Berliocchi; Amélie Bernard; Monique Bernard; Francesca Bernassola; Anne Bertolotti; Amanda S Bess; Sébastien Besteiro; Saverio Bettuzzi; Savita Bhalla; Shalmoli Bhattacharyya; Sujit K Bhutia; Caroline Biagosch; Michele Wolfe Bianchi; Martine Biard-Piechaczyk; Viktor Billes; Claudia Bincoletto; Baris Bingol; Sara W Bird; Marc Bitoun; Ivana Bjedov; Craig Blackstone; Lionel Blanc; Guillermo A Blanco; Heidi Kiil Blomhoff; Emilio Boada-Romero; Stefan Böckler; Marianne Boes; Kathleen Boesze-Battaglia; Lawrence H Boise; Alessandra Bolino; Andrea Boman; Paolo Bonaldo; Matteo Bordi; Jürgen Bosch; Luis M Botana; Joelle Botti; German Bou; Marina Bouché; Marion Bouchecareilh; Marie-Josée Boucher; Michael E Boulton; Sebastien G Bouret; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan Brady; Vania Mm Braga; Claudio Brancolini; Gerhard H Braus; José M Bravo-San Pedro; Lisa A Brennan; Emery H Bresnick; Patrick Brest; Dave Bridges; Marie-Agnès Bringer; Marisa Brini; Glauber C Brito; Bertha Brodin; Paul S Brookes; Eric J Brown; Karen Brown; Hal E Broxmeyer; Alain Bruhat; Patricia Chakur Brum; John H Brumell; Nicola Brunetti-Pierri; Robert J Bryson-Richardson; Shilpa Buch; Alastair M Buchan; Hikmet Budak; Dmitry V Bulavin; Scott J Bultman; Geert Bultynck; Vladimir Bumbasirevic; Yan Burelle; Robert E Burke; Margit Burmeister; Peter Bütikofer; Laura Caberlotto; Ken Cadwell; Monika Cahova; Dongsheng Cai; Jingjing Cai; Qian Cai; Sara Calatayud; Nadine Camougrand; Michelangelo Campanella; Grant R Campbell; Matthew Campbell; Silvia Campello; Robin Candau; Isabella Caniggia; Lavinia Cantoni; Lizhi Cao; Allan B Caplan; Michele Caraglia; Claudio Cardinali; Sandra Morais Cardoso; Jennifer S Carew; Laura A Carleton; Cathleen R Carlin; Silvia Carloni; Sven R Carlsson; Didac Carmona-Gutierrez; Leticia Am Carneiro; Oliana Carnevali; Serena Carra; Alice Carrier; Bernadette Carroll; Caty Casas; Josefina Casas; Giuliana Cassinelli; Perrine Castets; Susana Castro-Obregon; Gabriella Cavallini; Isabella Ceccherini; Francesco Cecconi; Arthur I Cederbaum; Valentín Ceña; Simone Cenci; Claudia Cerella; Davide Cervia; Silvia Cetrullo; Hassan Chaachouay; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Georgios Chamilos; Edmond Yw Chan; Matthew Tv Chan; Dhyan Chandra; Pallavi Chandra; Chih-Peng Chang; Raymond Chuen-Chung Chang; Ta Yuan Chang; John C Chatham; Saurabh Chatterjee; Santosh Chauhan; Yongsheng Che; Michael E Cheetham; Rajkumar Cheluvappa; Chun-Jung Chen; Gang Chen; Guang-Chao Chen; Guoqiang Chen; Hongzhuan Chen; Jeff W Chen; Jian-Kang Chen; Min Chen; Mingzhou Chen; Peiwen Chen; Qi Chen; Quan Chen; Shang-Der Chen; Si Chen; Steve S-L Chen; Wei Chen; Wei-Jung Chen; Wen Qiang Chen; Wenli Chen; Xiangmei Chen; Yau-Hung Chen; Ye-Guang Chen; Yin Chen; Yingyu Chen; Yongshun Chen; Yu-Jen Chen; Yue-Qin Chen; Yujie Chen; Zhen Chen; Zhong Chen; Alan Cheng; Christopher Hk Cheng; Hua Cheng; Heesun Cheong; Sara Cherry; Jason Chesney; Chun Hei Antonio Cheung; Eric Chevet; Hsiang Cheng Chi; Sung-Gil Chi; Fulvio Chiacchiera; Hui-Ling Chiang; Roberto Chiarelli; Mario Chiariello; Marcello Chieppa; Lih-Shen Chin; Mario Chiong; Gigi Nc Chiu; Dong-Hyung Cho; Ssang-Goo Cho; William C Cho; Yong-Yeon Cho; Young-Seok Cho; Augustine Mk Choi; Eui-Ju Choi; Eun-Kyoung Choi; Jayoung Choi; Mary E Choi; Seung-Il Choi; Tsui-Fen Chou; Salem Chouaib; Divaker Choubey; Vinay Choubey; Kuan-Chih Chow; Kamal Chowdhury; Charleen T Chu; Tsung-Hsien Chuang; Taehoon Chun; Hyewon Chung; Taijoon Chung; Yuen-Li Chung; Yong-Joon Chwae; Valentina Cianfanelli; Roberto Ciarcia; Iwona A Ciechomska; Maria Rosa Ciriolo; Mara Cirone; Sofie Claerhout; Michael J Clague; Joan Clària; Peter Gh Clarke; Robert Clarke; Emilio Clementi; Cédric Cleyrat; Miriam Cnop; Eliana M Coccia; Tiziana Cocco; Patrice Codogno; Jörn Coers; Ezra Ew Cohen; David Colecchia; Luisa Coletto; Núria S Coll; Emma Colucci-Guyon; Sergio Comincini; Maria Condello; Katherine L Cook; Graham H Coombs; Cynthia D Cooper; J Mark Cooper; Isabelle Coppens; Maria Tiziana Corasaniti; Marco Corazzari; Ramon Corbalan; Elisabeth Corcelle-Termeau; Mario D Cordero; Cristina Corral-Ramos; Olga Corti; Andrea Cossarizza; Paola Costelli; Safia Costes; Susan L Cotman; Ana Coto-Montes; Sandra Cottet; Eduardo Couve; Lori R Covey; L Ashley Cowart; Jeffery S Cox; Fraser P Coxon; Carolyn B Coyne; Mark S Cragg; Rolf J Craven; Tiziana Crepaldi; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Maria Teresa Cruz; Ana Maria Cuervo; Jose M Cuezva; Taixing Cui; Pedro R Cutillas; Mark J Czaja; Maria F Czyzyk-Krzeska; Ruben K Dagda; Uta Dahmen; Chunsun Dai; Wenjie Dai; Yun Dai; Kevin N Dalby; Luisa Dalla Valle; Guillaume Dalmasso; Marcello D'Amelio; Markus Damme; Arlette Darfeuille-Michaud; Catherine Dargemont; Victor M Darley-Usmar; Srinivasan Dasarathy; Biplab Dasgupta; Srikanta Dash; Crispin R Dass; Hazel Marie Davey; Lester M Davids; David Dávila; Roger J Davis; Ted M Dawson; Valina L Dawson; Paula Daza; Jackie de Belleroche; Paul de Figueiredo; Regina Celia Bressan Queiroz de Figueiredo; José de la Fuente; Luisa De Martino; Antonella De Matteis; Guido Ry De Meyer; Angelo De Milito; Mauro De Santi; Wanderley de Souza; Vincenzo De Tata; Daniela De Zio; Jayanta Debnath; Reinhard Dechant; Jean-Paul Decuypere; Shane Deegan; Benjamin Dehay; Barbara Del Bello; Dominic P Del Re; Régis Delage-Mourroux; Lea Md Delbridge; Louise Deldicque; Elizabeth Delorme-Axford; Yizhen Deng; Joern Dengjel; Melanie Denizot; Paul Dent; Channing J Der; Vojo Deretic; Benoît Derrien; Eric Deutsch; Timothy P Devarenne; Rodney J Devenish; Sabrina Di Bartolomeo; Nicola Di Daniele; Fabio Di Domenico; Alessia Di Nardo; Simone Di Paola; Antonio Di Pietro; Livia Di Renzo; Aaron DiAntonio; Guillermo Díaz-Araya; Ines Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Chad A Dickey; Robert C Dickson; Marc Diederich; Paul Digard; Ivan Dikic; Savithrama P Dinesh-Kumar; Chan Ding; Wen-Xing Ding; Zufeng Ding; Luciana Dini; Jörg Hw Distler; Abhinav Diwan; Mojgan Djavaheri-Mergny; Kostyantyn Dmytruk; Renwick Cj Dobson; Volker Doetsch; Karol Dokladny; Svetlana Dokudovskaya; Massimo Donadelli; X Charlie Dong; Xiaonan Dong; Zheng Dong; Terrence M Donohue; Kelly S Doran; Gabriella D'Orazi; Gerald W Dorn; Victor Dosenko; Sami Dridi; Liat Drucker; Jie Du; Li-Lin Du; Lihuan Du; André du Toit; Priyamvada Dua; Lei Duan; Pu Duann; Vikash Kumar Dubey; Michael R Duchen; Michel A Duchosal; Helene Duez; Isabelle Dugail; Verónica I Dumit; Mara C Duncan; Elaine A Dunlop; William A Dunn; Nicolas Dupont; Luc Dupuis; Raúl V Durán; Thomas M Durcan; Stéphane Duvezin-Caubet; Umamaheswar Duvvuri; Vinay Eapen; Darius Ebrahimi-Fakhari; Arnaud Echard; Leopold Eckhart; Charles L Edelstein; Aimee L Edinger; Ludwig Eichinger; Tobias Eisenberg; Avital Eisenberg-Lerner; N Tony Eissa; Wafik S El-Deiry; Victoria El-Khoury; Zvulun Elazar; Hagit Eldar-Finkelman; Chris Jh Elliott; Enzo Emanuele; Urban Emmenegger; Nikolai Engedal; Anna-Mart Engelbrecht; Simone Engelender; Jorrit M Enserink; Ralf Erdmann; Jekaterina Erenpreisa; Rajaraman Eri; Jason L Eriksen; Andreja Erman; Ricardo Escalante; Eeva-Liisa Eskelinen; Lucile Espert; Lorena Esteban-Martínez; Thomas J Evans; Mario Fabri; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Nils J Færgeman; Alberto Faggioni; W Douglas Fairlie; Chunhai Fan; Daping Fan; Jie Fan; Shengyun Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Mathias Faure; Francois B Favier; Howard Fearnhead; Massimo Federici; Erkang Fei; Tania C Felizardo; Hua Feng; Yibin Feng; Yuchen Feng; Thomas A Ferguson; Álvaro F Fernández; Maite G Fernandez-Barrena; Jose C Fernandez-Checa; Arsenio Fernández-López; Martin E Fernandez-Zapico; Olivier Feron; Elisabetta Ferraro; Carmen Veríssima Ferreira-Halder; Laszlo Fesus; Ralph Feuer; Fabienne C Fiesel; Eduardo C Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; John H Fingert; Steven Finkbeiner; Toren Finkel; Filomena Fiorito; Paul B Fisher; Marc Flajolet; Flavio Flamigni; Oliver Florey; Salvatore Florio; R Andres Floto; Marco Folini; Carlo Follo; Edward A Fon; Francesco Fornai; Franco Fortunato; Alessandro Fraldi; Rodrigo Franco; Arnaud Francois; Aurélie François; Lisa B Frankel; Iain Dc Fraser; Norbert Frey; Damien G Freyssenet; Christian Frezza; Scott L Friedman; Daniel E Frigo; Dongxu Fu; José M Fuentes; Juan Fueyo; Yoshio Fujitani; Yuuki Fujiwara; Mikihiro Fujiya; Mitsunori Fukuda; Simone Fulda; Carmela Fusco; Bozena Gabryel; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Sehamuddin Galadari; Gad Galili; Inmaculada Galindo; Maria F Galindo; Giovanna Galliciotti; Lorenzo Galluzzi; Luca Galluzzi; Vincent Galy; Noor Gammoh; Sam Gandy; Anand K Ganesan; Swamynathan Ganesan; Ian G Ganley; Monique Gannagé; Fen-Biao Gao; Feng Gao; Jian-Xin Gao; Lorena García Nannig; Eleonora García Véscovi; Marina Garcia-Macía; Carmen Garcia-Ruiz; Abhishek D Garg; Pramod Kumar Garg; Ricardo Gargini; Nils Christian Gassen; Damián Gatica; Evelina Gatti; Julie Gavard; Evripidis Gavathiotis; Liang Ge; Pengfei Ge; Shengfang Ge; Po-Wu Gean; Vania Gelmetti; Armando A Genazzani; Jiefei Geng; Pascal Genschik; Lisa Gerner; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Eric Ghigo; Debabrata Ghosh; Anna Maria Giammarioli; Francesca Giampieri; Claudia Giampietri; Alexandra Giatromanolaki; Derrick J Gibbings; Lara Gibellini; Spencer B Gibson; Vanessa Ginet; Antonio Giordano; Flaviano Giorgini; Elisa Giovannetti; Stephen E Girardin; Suzana Gispert; Sandy Giuliano; Candece L Gladson; Alvaro Glavic; Martin Gleave; Nelly Godefroy; Robert M Gogal; Kuppan Gokulan; Gustavo H Goldman; Delia Goletti; Michael S Goligorsky; Aldrin V Gomes; Ligia C Gomes; Hernando Gomez; Candelaria Gomez-Manzano; Rubén Gómez-Sánchez; Dawit Ap Gonçalves; Ebru Goncu; Qingqiu Gong; Céline Gongora; Carlos B Gonzalez; Pedro Gonzalez-Alegre; Pilar Gonzalez-Cabo; Rosa Ana González-Polo; Ing Swie Goping; Carlos Gorbea; Nikolai V Gorbunov; Daphne R Goring; Adrienne M Gorman; Sharon M Gorski; Sandro Goruppi; Shino Goto-Yamada; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Yacine Graba; Martin Graef; Giovanna E Granato; Gary Dean Grant; Steven Grant; Giovanni Luca Gravina; Douglas R Green; Alexander Greenhough; Michael T Greenwood; Benedetto Grimaldi; Frédéric Gros; Charles Grose; Jean-Francois Groulx; Florian Gruber; Paolo Grumati; Tilman Grune; Jun-Lin Guan; Kun-Liang Guan; Barbara Guerra; Carlos Guillen; Kailash Gulshan; Jan Gunst; Chuanyong Guo; Lei Guo; Ming Guo; Wenjie Guo; Xu-Guang Guo; Andrea A Gust; Åsa B Gustafsson; Elaine Gutierrez; Maximiliano G Gutierrez; Ho-Shin Gwak; Albert Haas; James E Haber; Shinji Hadano; Monica Hagedorn; David R Hahn; Andrew J Halayko; Anne Hamacher-Brady; Kozo Hamada; Ahmed Hamai; Andrea Hamann; Maho Hamasaki; Isabelle Hamer; Qutayba Hamid; Ester M Hammond; Feng Han; Weidong Han; James T Handa; John A Hanover; Malene Hansen; Masaru Harada; Ljubica Harhaji-Trajkovic; J Wade Harper; Abdel Halim Harrath; Adrian L Harris; James Harris; Udo Hasler; Peter Hasselblatt; Kazuhisa Hasui; Robert G Hawley; Teresa S Hawley; Congcong He; Cynthia Y He; Fengtian He; Gu He; Rong-Rong He; Xian-Hui He; You-Wen He; Yu-Ying He; Joan K Heath; Marie-Josée Hébert; Robert A Heinzen; Gudmundur Vignir Helgason; Michael Hensel; Elizabeth P Henske; Chengtao Her; Paul K Herman; Agustín Hernández; Carlos Hernandez; Sonia Hernández-Tiedra; Claudio Hetz; P Robin Hiesinger; Katsumi Higaki; Sabine Hilfiker; Bradford G Hill; Joseph A Hill; William D Hill; Keisuke Hino; Daniel Hofius; Paul Hofman; Günter U Höglinger; Jörg Höhfeld; Marina K Holz; Yonggeun Hong; David A Hood; Jeroen Jm Hoozemans; Thorsten Hoppe; Chin Hsu; Chin-Yuan Hsu; Li-Chung Hsu; Dong Hu; Guochang Hu; Hong-Ming Hu; Hongbo Hu; Ming Chang Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Ya Hua; Canhua Huang; Huey-Lan Huang; Kuo-How Huang; Kuo-Yang Huang; Shile Huang; Shiqian Huang; Wei-Pang Huang; Yi-Ran Huang; Yong Huang; Yunfei Huang; Tobias B Huber; Patricia Huebbe; Won-Ki Huh; Juha J Hulmi; Gang Min Hur; James H Hurley; Zvenyslava Husak; Sabah Na Hussain; Salik Hussain; Jung Jin Hwang; Seungmin Hwang; Thomas Is Hwang; Atsuhiro Ichihara; Yuzuru Imai; Carol Imbriano; Megumi Inomata; Takeshi Into; Valentina Iovane; Juan L Iovanna; Renato V Iozzo; Nancy Y Ip; Javier E Irazoqui; Pablo Iribarren; Yoshitaka Isaka; Aleksandra J Isakovic; Harry Ischiropoulos; Jeffrey S Isenberg; Mohammad Ishaq; Hiroyuki Ishida; Isao Ishii; Jane E Ishmael; Ciro Isidoro; Ken-Ichi Isobe; Erika Isono; Shohreh Issazadeh-Navikas; Koji Itahana; Eisuke Itakura; Andrei I Ivanov; Anand Krishnan V Iyer; José M Izquierdo; Yotaro Izumi; Valentina Izzo; Marja Jäättelä; Nadia Jaber; Daniel John Jackson; William T Jackson; Tony George Jacob; Thomas S Jacques; Chinnaswamy Jagannath; Ashish Jain; Nihar Ranjan Jana; Byoung Kuk Jang; Alkesh Jani; Bassam Janji; Paulo Roberto Jannig; Patric J Jansson; Steve Jean; Marina Jendrach; Ju-Hong Jeon; Niels Jessen; Eui-Bae Jeung; Kailiang Jia; Lijun Jia; Hong Jiang; Hongchi Jiang; Liwen Jiang; Teng Jiang; Xiaoyan Jiang; Xuejun Jiang; Xuejun Jiang; Ying Jiang; Yongjun Jiang; Alberto Jiménez; Cheng Jin; Hongchuan Jin; Lei Jin; Meiyan Jin; Shengkan Jin; Umesh Kumar Jinwal; Eun-Kyeong Jo; Terje Johansen; Daniel E Johnson; Gail Vw Johnson; James D Johnson; Eric Jonasch; Chris Jones; Leo Ab Joosten; Joaquin Jordan; Anna-Maria Joseph; Bertrand Joseph; Annie M Joubert; Dianwen Ju; Jingfang Ju; Hsueh-Fen Juan; Katrin Juenemann; Gábor Juhász; Hye Seung Jung; Jae U Jung; Yong-Keun Jung; Heinz Jungbluth; Matthew J Justice; Barry Jutten; Nadeem O Kaakoush; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Bertrand Kaeffer; Katarina Kågedal; Alon Kahana; Shingo Kajimura; Or Kakhlon; Manjula Kalia; Dhan V Kalvakolanu; Yoshiaki Kamada; Konstantinos Kambas; Vitaliy O Kaminskyy; Harm H Kampinga; Mustapha Kandouz; Chanhee Kang; Rui Kang; Tae-Cheon Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Marc Kantorow; Maria Kaparakis-Liaskos; Orsolya Kapuy; Vassiliki Karantza; Md Razaul Karim; Parimal Karmakar; Arthur Kaser; Susmita Kaushik; Thomas Kawula; A Murat Kaynar; Po-Yuan Ke; Zun-Ji Ke; John H Kehrl; Kate E Keller; Jongsook Kim Kemper; Anne K Kenworthy; Oliver Kepp; Andreas Kern; Santosh Kesari; David Kessel; Robin Ketteler; Isis do Carmo Kettelhut; Bilon Khambu; Muzamil Majid Khan; Vinoth Km Khandelwal; Sangeeta Khare; Juliann G Kiang; Amy A Kiger; Akio Kihara; Arianna L Kim; Cheol Hyeon Kim; Deok Ryong Kim; Do-Hyung Kim; Eung Kweon Kim; Hye Young Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; Jin Hyoung Kim; Kwang Woon Kim; Michael D Kim; Moon-Moo Kim; Peter K Kim; Seong Who Kim; Soo-Youl Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Jason S King; Karla Kirkegaard; Vladimir Kirkin; Lorrie A Kirshenbaum; Shuji Kishi; Yasuo Kitajima; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Rudolf A Kley; Walter T Klimecki; Michael Klinkenberg; Jochen Klucken; Helene Knævelsrud; Erwin Knecht; Laura Knuppertz; Jiunn-Liang Ko; Satoru Kobayashi; Jan C Koch; Christelle Koechlin-Ramonatxo; Ulrich Koenig; Young Ho Koh; Katja Köhler; Sepp D Kohlwein; Masato Koike; Masaaki Komatsu; Eiki Kominami; Dexin Kong; Hee Jeong Kong; Eumorphia G Konstantakou; Benjamin T Kopp; Tamas Korcsmaros; Laura Korhonen; Viktor I Korolchuk; Nadya V Koshkina; Yanjun Kou; Michael I Koukourakis; Constantinos Koumenis; Attila L Kovács; Tibor Kovács; Werner J Kovacs; Daisuke Koya; Claudine Kraft; Dimitri Krainc; Helmut Kramer; Tamara Kravic-Stevovic; Wilhelm Krek; Carole Kretz-Remy; Roswitha Krick; Malathi Krishnamurthy; Janos Kriston-Vizi; Guido Kroemer; Michael C Kruer; Rejko Kruger; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Christian Kuhn; Addanki Pratap Kumar; Anuj Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Rakesh Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Atsushi Kuno; Sheng-Han Kuo; Jeff Kuret; Tino Kurz; Terry Kwok; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert R La Spada; Frank Lafont; Tim Lahm; Aparna Lakkaraju; Truong Lam; Trond Lamark; Steve Lancel; Terry H Landowski; Darius J R Lane; Jon D Lane; Cinzia Lanzi; Pierre Lapaquette; Louis R Lapierre; Jocelyn Laporte; Johanna Laukkarinen; Gordon W Laurie; Sergio Lavandero; Lena Lavie; Matthew J LaVoie; Betty Yuen Kwan Law; Helen Ka-Wai Law; Kelsey B Law; Robert Layfield; Pedro A Lazo; Laurent Le Cam; Karine G Le Roch; Hervé Le Stunff; Vijittra Leardkamolkarn; Marc Lecuit; Byung-Hoon Lee; Che-Hsin Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Hsinyu Lee; Jae Keun Lee; Jongdae Lee; Ju-Hyun Lee; Jun Hee Lee; Michael Lee; Myung-Shik Lee; Patty J Lee; Sam W Lee; Seung-Jae Lee; Shiow-Ju Lee; Stella Y Lee; Sug Hyung Lee; Sung Sik Lee; Sung-Joon Lee; Sunhee Lee; Ying-Ray Lee; Yong J Lee; Young H Lee; Christiaan Leeuwenburgh; Sylvain Lefort; Renaud Legouis; Jinzhi Lei; Qun-Ying Lei; David A Leib; Gil Leibowitz; Istvan Lekli; Stéphane D Lemaire; John J Lemasters; Marius K Lemberg; Antoinette Lemoine; Shuilong Leng; Guido Lenz; Paola Lenzi; Lilach O Lerman; Daniele Lettieri Barbato; Julia I-Ju Leu; Hing Y Leung; Beth Levine; Patrick A Lewis; Frank Lezoualc'h; Chi Li; Faqiang Li; Feng-Jun Li; Jun Li; Ke Li; Lian Li; Min Li; Min Li; Qiang Li; Rui Li; Sheng Li; Wei Li; Wei Li; Xiaotao Li; Yumin Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Yulin Liao; Joana Liberal; Pawel P Liberski; Pearl Lie; Andrew P Lieberman; Hyunjung Jade Lim; Kah-Leong Lim; Kyu Lim; Raquel T Lima; Chang-Shen Lin; Chiou-Feng Lin; Fang Lin; Fangming Lin; Fu-Cheng Lin; Kui Lin; Kwang-Huei Lin; Pei-Hui Lin; Tianwei Lin; Wan-Wan Lin; Yee-Shin Lin; Yong Lin; Rafael Linden; Dan Lindholm; Lisa M Lindqvist; Paul Lingor; Andreas Linkermann; Lance A Liotta; Marta M Lipinski; Vitor A Lira; Michael P Lisanti; Paloma B Liton; Bo Liu; Chong Liu; Chun-Feng Liu; Fei Liu; Hung-Jen Liu; Jianxun Liu; Jing-Jing Liu; Jing-Lan Liu; Ke Liu; Leyuan Liu; Liang Liu; Quentin Liu; Rong-Yu Liu; Shiming Liu; Shuwen Liu; Wei Liu; Xian-De Liu; Xiangguo Liu; Xiao-Hong Liu; Xinfeng Liu; Xu Liu; Xueqin Liu; Yang Liu; Yule Liu; Zexian Liu; Zhe Liu; Juan P Liuzzi; Gérard Lizard; Mila Ljujic; Irfan J Lodhi; Susan E Logue; Bal L Lokeshwar; Yun Chau Long; Sagar Lonial; Benjamin Loos; Carlos López-Otín; Cristina López-Vicario; Mar Lorente; Philip L Lorenzi; Péter Lõrincz; Marek Los; Michael T Lotze; Penny E Lovat; Binfeng Lu; Bo Lu; Jiahong Lu; Qing Lu; She-Min Lu; Shuyan Lu; Yingying Lu; Frédéric Luciano; Shirley Luckhart; John Milton Lucocq; Paula Ludovico; Aurelia Lugea; Nicholas W Lukacs; Julian J Lum; Anders H Lund; Honglin Luo; Jia Luo; Shouqing Luo; Claudio Luparello; Timothy Lyons; Jianjie Ma; Yi Ma; Yong Ma; Zhenyi Ma; Juliano Machado; Glaucia M Machado-Santelli; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; John D MacMicking; Lee Ann MacMillan-Crow; Frank Madeo; Muniswamy Madesh; Julio Madrigal-Matute; Akiko Maeda; Tatsuya Maeda; Gustavo Maegawa; Emilia Maellaro; Hannelore Maes; Marta Magariños; Kenneth Maiese; Tapas K Maiti; Luigi Maiuri; Maria Chiara Maiuri; Carl G Maki; Roland Malli; Walter Malorni; Alina Maloyan; Fathia Mami-Chouaib; Na Man; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Serge N Manié; Claudia Manzoni; Kai Mao; Zixu Mao; Zong-Wan Mao; Philippe Marambaud; Anna Maria Marconi; Zvonimir Marelja; Gabriella Marfe; Marta Margeta; Eva Margittai; Muriel Mari; Francesca V Mariani; Concepcio Marin; Sara Marinelli; Guillermo Mariño; Ivanka Markovic; Rebecca Marquez; Alberto M Martelli; Sascha Martens; Katie R Martin; Seamus J Martin; Shaun Martin; Miguel A Martin-Acebes; Paloma Martín-Sanz; Camille Martinand-Mari; Wim Martinet; Jennifer Martinez; Nuria Martinez-Lopez; Ubaldo Martinez-Outschoorn; Moisés Martínez-Velázquez; Marta Martinez-Vicente; Waleska Kerllen Martins; Hirosato Mashima; James A Mastrianni; Giuseppe Matarese; Paola Matarrese; Roberto Mateo; Satoaki Matoba; Naomichi Matsumoto; Takehiko Matsushita; Akira Matsuura; Takeshi Matsuzawa; Mark P Mattson; Soledad Matus; Norma Maugeri; Caroline Mauvezin; Andreas Mayer; Dusica Maysinger; Guillermo D Mazzolini; Mary Kate McBrayer; Kimberly McCall; Craig McCormick; Gerald M McInerney; Skye C McIver; Sharon McKenna; John J McMahon; Iain A McNeish; Fatima Mechta-Grigoriou; Jan Paul Medema; Diego L Medina; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Yide Mei; Ute-Christiane Meier; Alfred J Meijer; Alicia Meléndez; Gerry Melino; Sonia Melino; Edesio Jose Tenorio de Melo; Maria A Mena; Marc D Meneghini; Javier A Menendez; Regina Menezes; Liesu Meng; Ling-Hua Meng; Songshu Meng; Rossella Menghini; A Sue Menko; Rubem Fs Menna-Barreto; Manoj B Menon; Marco A Meraz-Ríos; Giuseppe Merla; Luciano Merlini; Angelica M Merlot; Andreas Meryk; Stefania Meschini; Joel N Meyer; Man-Tian Mi; Chao-Yu Miao; Lucia Micale; Simon Michaeli; Carine Michiels; Anna Rita Migliaccio; Anastasia Susie Mihailidou; Dalibor Mijaljica; Katsuhiko Mikoshiba; Enrico Milan; Leonor Miller-Fleming; Gordon B Mills; Ian G Mills; Georgia Minakaki; Berge A Minassian; Xiu-Fen Ming; Farida Minibayeva; Elena A Minina; Justine D Mintern; Saverio Minucci; Antonio Miranda-Vizuete; Claire H Mitchell; Shigeki Miyamoto; Keisuke Miyazawa; Noboru Mizushima; Katarzyna Mnich; Baharia Mograbi; Simin Mohseni; Luis Ferreira Moita; Marco Molinari; Maurizio Molinari; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Marco Mongillo; Martha M Monick; Serena Montagnaro; Craig Montell; Darren J Moore; Michael N Moore; Rodrigo Mora-Rodriguez; Paula I Moreira; Etienne Morel; Maria Beatrice Morelli; Sandra Moreno; Michael J Morgan; Arnaud Moris; Yuji Moriyasu; Janna L Morrison; Lynda A Morrison; Eugenia Morselli; Jorge Moscat; Pope L Moseley; Serge Mostowy; Elisa Motori; Denis Mottet; Jeremy C Mottram; Charbel E-H Moussa; Vassiliki E Mpakou; Hasan Mukhtar; Jean M Mulcahy Levy; Sylviane Muller; Raquel Muñoz-Moreno; Cristina Muñoz-Pinedo; Christian Münz; Maureen E Murphy; James T Murray; Aditya Murthy; Indira U Mysorekar; Ivan R Nabi; Massimo Nabissi; Gustavo A Nader; Yukitoshi Nagahara; Yoshitaka Nagai; Kazuhiro Nagata; Anika Nagelkerke; Péter Nagy; Samisubbu R Naidu; Sreejayan Nair; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Gennaro Napolitano; Naweed I Naqvi; Roberta Nardacci; Derek P Narendra; Masashi Narita; Anna Chiara Nascimbeni; Ramesh Natarajan; Luiz C Navegantes; Steffan T Nawrocki; Taras Y Nazarko; Volodymyr Y Nazarko; Thomas Neill; Luca M Neri; Mihai G Netea; Romana T Netea-Maier; Bruno M Neves; Paul A Ney; Ioannis P Nezis; Hang Tt Nguyen; Huu Phuc Nguyen; Anne-Sophie Nicot; Hilde Nilsen; Per Nilsson; Mikio Nishimura; Ichizo Nishino; Mireia Niso-Santano; Hua Niu; Ralph A Nixon; Vincent Co Njar; Takeshi Noda; Angelika A Noegel; Elsie Magdalena Nolte; Erik Norberg; Koenraad K Norga; Sakineh Kazemi Noureini; Shoji Notomi; Lucia Notterpek; Karin Nowikovsky; Nobuyuki Nukina; Thorsten Nürnberger; Valerie B O'Donnell; Tracey O'Donovan; Peter J O'Dwyer; Ina Oehme; Clara L Oeste; Michinaga Ogawa; Besim Ogretmen; Yuji Ogura; Young J Oh; Masaki Ohmuraya; Takayuki Ohshima; Rani Ojha; Koji Okamoto; Toshiro Okazaki; F Javier Oliver; Karin Ollinger; Stefan Olsson; Daniel P Orban; Paulina Ordonez; Idil Orhon; Laszlo Orosz; Eyleen J O'Rourke; Helena Orozco; Angel L Ortega; Elena Ortona; Laura D Osellame; Junko Oshima; Shigeru Oshima; Heinz D Osiewacz; Takanobu Otomo; Kinya Otsu; Jing-Hsiung James Ou; Tiago F Outeiro; Dong-Yun Ouyang; Hongjiao Ouyang; Michael Overholtzer; Michelle A Ozbun; P Hande Ozdinler; Bulent Ozpolat; Consiglia Pacelli; Paolo Paganetti; Guylène Page; Gilles Pages; Ugo Pagnini; Beata Pajak; Stephen C Pak; Karolina Pakos-Zebrucka; Nazzy Pakpour; Zdena Palková; Francesca Palladino; Kathrin Pallauf; Nicolas Pallet; Marta Palmieri; Søren R Paludan; Camilla Palumbo; Silvia Palumbo; Olatz Pampliega; Hongming Pan; Wei Pan; Theocharis Panaretakis; Aseem Pandey; Areti Pantazopoulou; Zuzana Papackova; Daniela L Papademetrio; Issidora Papassideri; Alessio Papini; Nirmala Parajuli; Julian Pardo; Vrajesh V Parekh; Giancarlo Parenti; Jong-In Park; Junsoo Park; Ohkmae K Park; Roy Parker; Rosanna Parlato; Jan B Parys; Katherine R Parzych; Jean-Max Pasquet; Benoit Pasquier; Kishore Bs Pasumarthi; Daniel Patschan; Cam Patterson; Sophie Pattingre; Scott Pattison; Arnim Pause; Hermann Pavenstädt; Flaminia Pavone; Zully Pedrozo; Fernando J Peña; Miguel A Peñalva; Mario Pende; Jianxin Peng; Fabio Penna; Josef M Penninger; Anna Pensalfini; Salvatore Pepe; Gustavo Js Pereira; Paulo C Pereira; Verónica Pérez-de la Cruz; María Esther Pérez-Pérez; Diego Pérez-Rodríguez; Dolores Pérez-Sala; Celine Perier; Andras Perl; David H Perlmutter; Ida Perrotta; Shazib Pervaiz; Maija Pesonen; Jeffrey E Pessin; Godefridus J Peters; Morten Petersen; Irina Petrache; Basil J Petrof; Goran Petrovski; James M Phang; Mauro Piacentini; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Federico Pietrocola; Felipe X Pimentel-Muiños; Mario Pinar; Benjamin Pineda; Ronit Pinkas-Kramarski; Marcello Pinti; Paolo Pinton; Bilal Piperdi; James M Piret; Leonidas C Platanias; Harald W Platta; Edward D Plowey; Stefanie Pöggeler; Marc Poirot; Peter Polčic; Angelo Poletti; Audrey H Poon; Hana Popelka; Blagovesta Popova; Izabela Poprawa; Shibu M Poulose; Joanna Poulton; Scott K Powers; Ted Powers; Mercedes Pozuelo-Rubio; Krisna Prak; Reinhild Prange; Mark Prescott; Muriel Priault; Sharon Prince; Richard L Proia; Tassula Proikas-Cezanne; Holger Prokisch; Vasilis J Promponas; Karin Przyklenk; Rosa Puertollano; Subbiah Pugazhenthi; Luigi Puglielli; Aurora Pujol; Julien Puyal; Dohun Pyeon; Xin Qi; Wen-Bin Qian; Zheng-Hong Qin; Yu Qiu; Ziwei Qu; Joe Quadrilatero; Frederick Quinn; Nina Raben; Hannah Rabinowich; Flavia Radogna; Michael J Ragusa; Mohamed Rahmani; Komal Raina; Sasanka Ramanadham; Rajagopal Ramesh; Abdelhaq Rami; Sarron Randall-Demllo; Felix Randow; Hai Rao; V Ashutosh Rao; Blake B Rasmussen; Tobias M Rasse; Edward A Ratovitski; Pierre-Emmanuel Rautou; Swapan K Ray; Babak Razani; Bruce H Reed; Fulvio Reggiori; Markus Rehm; Andreas S Reichert; Theo Rein; David J Reiner; Eric Reits; Jun Ren; Xingcong Ren; Maurizio Renna; Jane Eb Reusch; Jose L Revuelta; Leticia Reyes; Alireza R Rezaie; Robert I Richards; Des R Richardson; Clémence Richetta; Michael A Riehle; Bertrand H Rihn; Yasuko Rikihisa; Brigit E Riley; Gerald Rimbach; Maria Rita Rippo; Konstantinos Ritis; Federica Rizzi; Elizete Rizzo; Peter J Roach; Jeffrey Robbins; Michel Roberge; Gabriela Roca; Maria Carmela Roccheri; Sonia Rocha; Cecilia Mp Rodrigues; Clara I Rodríguez; Santiago Rodriguez de Cordoba; Natalia Rodriguez-Muela; Jeroen Roelofs; Vladimir V Rogov; Troy T Rohn; Bärbel Rohrer; Davide Romanelli; Luigina Romani; Patricia Silvia Romano; M Isabel G Roncero; Jose Luis Rosa; Alicia Rosello; Kirill V Rosen; Philip Rosenstiel; Magdalena Rost-Roszkowska; Kevin A Roth; Gael Roué; Mustapha Rouis; Kasper M Rouschop; Daniel T Ruan; Diego Ruano; David C Rubinsztein; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Ruediger Rudolf; Markus A Ruegg; Carmen Ruiz-Roldan; Avnika Ashok Ruparelia; Paola Rusmini; David W Russ; Gian Luigi Russo; Giuseppe Russo; Rossella Russo; Tor Erik Rusten; Victoria Ryabovol; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Michael Sacher; Carsten Sachse; Michael N Sack; Junichi Sadoshima; Paul Saftig; Ronit Sagi-Eisenberg; Sumit Sahni; Pothana Saikumar; Tsunenori Saito; Tatsuya Saitoh; Koichi Sakakura; Machiko Sakoh-Nakatogawa; Yasuhito Sakuraba; María Salazar-Roa; Paolo Salomoni; Ashok K Saluja; Paul M Salvaterra; Rosa Salvioli; Afshin Samali; Anthony Mj Sanchez; José A Sánchez-Alcázar; Ricardo Sanchez-Prieto; Marco Sandri; Miguel A Sanjuan; Stefano Santaguida; Laura Santambrogio; Giorgio Santoni; Claudia Nunes Dos Santos; Shweta Saran; Marco Sardiello; Graeme Sargent; Pallabi Sarkar; Sovan Sarkar; Maria Rosa Sarrias; Minnie M Sarwal; Chihiro Sasakawa; Motoko Sasaki; Miklos Sass; Ken Sato; Miyuki Sato; Joseph Satriano; Niramol Savaraj; Svetlana Saveljeva; Liliana Schaefer; Ulrich E Schaible; Michael Scharl; Hermann M Schatzl; Randy Schekman; Wiep Scheper; Alfonso Schiavi; Hyman M Schipper; Hana Schmeisser; Jens Schmidt; Ingo Schmitz; Bianca E Schneider; E Marion Schneider; Jaime L Schneider; Eric A Schon; Miriam J Schönenberger; Axel H Schönthal; Daniel F Schorderet; Bernd Schröder; Sebastian Schuck; Ryan J Schulze; Melanie Schwarten; Thomas L Schwarz; Sebastiano Sciarretta; Kathleen Scotto; A Ivana Scovassi; Robert A Screaton; Mark Screen; Hugo Seca; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Jose M Seguí-Simarro; Juan Segura-Aguilar; Ekihiro Seki; Christian Sell; Iban Seiliez; Clay F Semenkovich; Gregg L Semenza; Utpal Sen; Andreas L Serra; Ana Serrano-Puebla; Hiromi Sesaki; Takao Setoguchi; Carmine Settembre; John J Shacka; Ayesha N Shajahan-Haq; Irving M Shapiro; Shweta Sharma; Hua She; C-K James Shen; Chiung-Chyi Shen; Han-Ming Shen; Sanbing Shen; Weili Shen; Rui Sheng; Xianyong Sheng; Zu-Hang Sheng; Trevor G Shepherd; Junyan Shi; Qiang Shi; Qinghua Shi; Yuguang Shi; Shusaku Shibutani; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Dong Wook Shin; Mari L Shinohara; Michiko Shintani; Takahiro Shintani; Tetsuo Shioi; Ken Shirabe; Ronit Shiri-Sverdlov; Orian Shirihai; Gordon C Shore; Chih-Wen Shu; Deepak Shukla; Andriy A Sibirny; Valentina Sica; Christina J Sigurdson; Einar M Sigurdsson; Puran Singh Sijwali; Beata Sikorska; Wilian A Silveira; Sandrine Silvente-Poirot; Gary A Silverman; Jan Simak; Thomas Simmet; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Matias Simons; Anne Simonsen; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Debasish Sinha; Sangita Sinha; Frank A Sinicrope; Agnieszka Sirko; Kapil Sirohi; Balindiwe Jn Sishi; Annie Sittler; Parco M Siu; Efthimios Sivridis; Anna Skwarska; Ruth Slack; Iva Slaninová; Nikolai Slavov; Soraya S Smaili; Keiran Sm Smalley; Duncan R Smith; Stefaan J Soenen; Scott A Soleimanpour; Anita Solhaug; Kumaravel Somasundaram; Jin H Son; Avinash Sonawane; Chunjuan Song; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Wei Song; Kai Y Soo; Anil K Sood; Tuck Wah Soong; Virawudh Soontornniyomkij; Maurizio Sorice; Federica Sotgia; David R Soto-Pantoja; Areechun Sotthibundhu; Maria João Sousa; Herman P Spaink; Paul N Span; Anne Spang; Janet D Sparks; Peter G Speck; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Daret St Clair; Alessandra Stacchiotti; Bart Staels; Michael T Stang; Daniel T Starczynowski; Petro Starokadomskyy; Clemens Steegborn; John W Steele; Leonidas Stefanis; Joan Steffan; Christine M Stellrecht; Harald Stenmark; Tomasz M Stepkowski; Stęphan T Stern; Craig Stevens; Brent R Stockwell; Veronika Stoka; Zuzana Storchova; Björn Stork; Vassilis Stratoulias; Dimitrios J Stravopodis; Pavel Strnad; Anne Marie Strohecker; Anna-Lena Ström; Per Stromhaug; Jiri Stulik; Yu-Xiong Su; Zhaoliang Su; Carlos S Subauste; Srinivasa Subramaniam; Carolyn M Sue; Sang Won Suh; Xinbing Sui; Supawadee Sukseree; David Sulzer; Fang-Lin Sun; Jiaren Sun; Jun Sun; Shi-Yong Sun; Yang Sun; Yi Sun; Yingjie Sun; Vinod Sundaramoorthy; Joseph Sung; Hidekazu Suzuki; Kuninori Suzuki; Naoki Suzuki; Tadashi Suzuki; Yuichiro J Suzuki; Michele S Swanson; Charles Swanton; Karl Swärd; Ghanshyam Swarup; Sean T Sweeney; Paul W Sylvester; Zsuzsanna Szatmari; Eva Szegezdi; Peter W Szlosarek; Heinrich Taegtmeyer; Marco Tafani; Emmanuel Taillebourg; Stephen Wg Tait; Krisztina Takacs-Vellai; Yoshinori Takahashi; Szabolcs Takáts; Genzou Takemura; Nagio Takigawa; Nicholas J Talbot; Elena Tamagno; Jerome Tamburini; Cai-Ping Tan; Lan Tan; Mei Lan Tan; Ming Tan; Yee-Joo Tan; Keiji Tanaka; Masaki Tanaka; Daolin Tang; Dingzhong Tang; Guomei Tang; Isei Tanida; Kunikazu Tanji; Bakhos A Tannous; Jose A Tapia; Inmaculada Tasset-Cuevas; Marc Tatar; Iman Tavassoly; Nektarios Tavernarakis; Allen Taylor; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Mark J Taylor; Elena V Tchetina; Andrew R Tee; Fatima Teixeira-Clerc; Sucheta Telang; Tewin Tencomnao; Ba-Bie Teng; Ru-Jeng Teng; Faraj Terro; Gianluca Tettamanti; Arianne L Theiss; Anne E Theron; Kelly Jean Thomas; Marcos P Thomé; Paul G Thomes; Andrew Thorburn; Jeremy Thorner; Thomas Thum; Michael Thumm; Teresa Lm Thurston; Ling Tian; Andreas Till; Jenny Pan-Yun Ting; Vladimir I Titorenko; Lilach Toker; Stefano Toldo; Sharon A Tooze; Ivan Topisirovic; Maria Lyngaas Torgersen; Liliana Torosantucci; Alicia Torriglia; Maria Rosaria Torrisi; Cathy Tournier; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Gemma Triola; Durga Nand Tripathi; Daniela Trisciuoglio; Rodrigo Troncoso; Ioannis P Trougakos; Anita C Truttmann; Kuen-Jer Tsai; Mario P Tschan; Yi-Hsin Tseng; Takayuki Tsukuba; Allan Tsung; Andrey S Tsvetkov; Shuiping Tu; Hsing-Yu Tuan; Marco Tucci; David A Tumbarello; Boris Turk; Vito Turk; Robin Fb Turner; Anders A Tveita; Suresh C Tyagi; Makoto Ubukata; Yasuo Uchiyama; Andrej Udelnow; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Benjamin R Underwood; Christian Ungermann; Rodrigo P Ureshino; Ryo Ushioda; Vladimir N Uversky; Néstor L Uzcátegui; Thomas Vaccari; Maria I Vaccaro; Libuše Váchová; Helin Vakifahmetoglu-Norberg; Rut Valdor; Enza Maria Valente; Francois Vallette; Angela M Valverde; Greet Van den Berghe; Ludo Van Den Bosch; Gijs R van den Brink; F Gisou van der Goot; Ida J van der Klei; Luc Jw van der Laan; Wouter G van Doorn; Marjolein van Egmond; Kenneth L van Golen; Luc Van Kaer; Menno van Lookeren Campagne; Peter Vandenabeele; Wim Vandenberghe; Ilse Vanhorebeek; Isabel Varela-Nieto; M Helena Vasconcelos; Radovan Vasko; Demetrios G Vavvas; Ignacio Vega-Naredo; Guillermo Velasco; Athanassios D Velentzas; Panagiotis D Velentzas; Tibor Vellai; Edo Vellenga; Mikkel Holm Vendelbo; Kartik Venkatachalam; Natascia Ventura; Salvador Ventura; Patrícia St Veras; Mireille Verdier; Beata G Vertessy; Andrea Viale; Michel Vidal; Helena L A Vieira; Richard D Vierstra; Nadarajah Vigneswaran; Neeraj Vij; Miquel Vila; Margarita Villar; Victor H Villar; Joan Villarroya; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Giovanni Vitale; Dan T Vogl; Olga V Voitsekhovskaja; Clarissa von Haefen; Karin von Schwarzenberg; Daniel E Voth; Valérie Vouret-Craviari; Kristina Vuori; Jatin M Vyas; Christian Waeber; Cheryl Lyn Walker; Mark J Walker; Jochen Walter; Lei Wan; Xiangbo Wan; Bo Wang; Caihong Wang; Chao-Yung Wang; Chengshu Wang; Chenran Wang; Chuangui Wang; Dong Wang; Fen Wang; Fuxin Wang; Guanghui Wang; Hai-Jie Wang; Haichao Wang; Hong-Gang Wang; Hongmin Wang; Horng-Dar Wang; Jing Wang; Junjun Wang; Mei Wang; Mei-Qing Wang; Pei-Yu Wang; Peng Wang; Richard C Wang; Shuo Wang; Ting-Fang Wang; Xian Wang; Xiao-Jia Wang; Xiao-Wei Wang; Xin Wang; Xuejun Wang; Yan Wang; Yanming Wang; Ying Wang; Ying-Jan Wang; Yipeng Wang; Yu Wang; Yu Tian Wang; Yuqing Wang; Zhi-Nong Wang; Pablo Wappner; Carl Ward; Diane McVey Ward; Gary Warnes; Hirotaka Watada; Yoshihisa Watanabe; Kei Watase; Timothy E Weaver; Colin D Weekes; Jiwu Wei; Thomas Weide; Conrad C Weihl; Günther Weindl; Simone Nardin Weis; Longping Wen; Xin Wen; Yunfei Wen; Benedikt Westermann; Cornelia M Weyand; Anthony R White; Eileen White; J Lindsay Whitton; Alexander J Whitworth; Joëlle Wiels; Franziska Wild; Manon E Wildenberg; Tom Wileman; Deepti Srinivas Wilkinson; Simon Wilkinson; Dieter Willbold; Chris Williams; Katherine Williams; Peter R Williamson; Konstanze F Winklhofer; Steven S Witkin; Stephanie E Wohlgemuth; Thomas Wollert; Ernst J Wolvetang; Esther Wong; G William Wong; Richard W Wong; Vincent Kam Wai Wong; Elizabeth A Woodcock; Karen L Wright; Chunlai Wu; Defeng Wu; Gen Sheng Wu; Jian Wu; Junfang Wu; Mian Wu; Min Wu; Shengzhou Wu; William Kk Wu; Yaohua Wu; Zhenlong Wu; Cristina Pr Xavier; Ramnik J Xavier; Gui-Xian Xia; Tian Xia; Weiliang Xia; Yong Xia; Hengyi Xiao; Jian Xiao; Shi Xiao; Wuhan Xiao; Chuan-Ming Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Yuyan Xiong; Chuanshan Xu; Congfeng Xu; Feng Xu; Haoxing Xu; Hongwei Xu; Jian Xu; Jianzhen Xu; Jinxian Xu; Liang Xu; Xiaolei Xu; Yangqing Xu; Ye Xu; Zhi-Xiang Xu; Ziheng Xu; Yu Xue; Takahiro Yamada; Ai Yamamoto; Koji Yamanaka; Shunhei Yamashina; Shigeko Yamashiro; Bing Yan; Bo Yan; Xianghua Yan; Zhen Yan; Yasuo Yanagi; Dun-Sheng Yang; Jin-Ming Yang; Liu Yang; Minghua Yang; Pei-Ming Yang; Peixin Yang; Qian Yang; Wannian Yang; Wei Yuan Yang; Xuesong Yang; Yi Yang; Ying Yang; Zhifen Yang; Zhihong Yang; Meng-Chao Yao; Pamela J Yao; Xiaofeng Yao; Zhenyu Yao; Zhiyuan Yao; Linda S Yasui; Mingxiang Ye; Barry Yedvobnick; Behzad Yeganeh; Elizabeth S Yeh; Patricia L Yeyati; Fan Yi; Long Yi; Xiao-Ming Yin; Calvin K Yip; Yeong-Min Yoo; Young Hyun Yoo; Seung-Yong Yoon; Ken-Ichi Yoshida; Tamotsu Yoshimori; Ken H Young; Huixin Yu; Jane J Yu; Jin-Tai Yu; Jun Yu; Li Yu; W Haung Yu; Xiao-Fang Yu; Zhengping Yu; Junying Yuan; Zhi-Min Yuan; Beatrice Yjt Yue; Jianbo Yue; Zhenyu Yue; David N Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Tania Zaglia; Zahra Zakeri; Vincent Zecchini; Jinsheng Zeng; Min Zeng; Qi Zeng; Antonis S Zervos; Donna D Zhang; Fan Zhang; Guo Zhang; Guo-Chang Zhang; Hao Zhang; Hong Zhang; Hong Zhang; Hongbing Zhang; Jian Zhang; Jian Zhang; Jiangwei Zhang; Jianhua Zhang; Jing-Pu Zhang; Li Zhang; Lin Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xiangnan Zhang; Xu Dong Zhang; Yan Zhang; Yang Zhang; Yanjin Zhang; Yingmei Zhang; Yunjiao Zhang; Mei Zhao; Wei-Li Zhao; Xiaonan Zhao; Yan G Zhao; Ying Zhao; Yongchao Zhao; Yu-Xia Zhao; Zhendong Zhao; Zhizhuang J Zhao; Dexian Zheng; Xi-Long Zheng; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Guang-Zhou Zhou; Guofei Zhou; Huiping Zhou; Shu-Feng Zhou; Xu-Jie Zhou; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Wenhua Zhu; Xiao-Feng Zhu; Yuhua Zhu; Shi-Mei Zhuang; Xiaohong Zhuang; Elio Ziparo; Christos E Zois; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Susu M Zughaier Journal: Autophagy Date: 2016 Impact factor: 16.016